Although ccRCC tumors are molecularly and immunologically heterogeneous, the focus of this minireview is to identify additional biomarkers altered in ccRCC other than VEGF and PD-L1 that can be effectively downregulated by nontoxic doses of selenium. Here, VEGFA is linked to nonpapillary renal cell carcinoma.